Decision Resources Group (DRG) is a global information & technology services company providing proprietary data and solutions to the healthcare industry.
Location: United States, Massachusetts, Burlington
Employees: 1001-5000
Phone: +1 781-993-2500
Investors 1
| Date | Name | Website |
| - | Providence... | provequity... |
Mentions in press and media 9
| Date | Title | Description |
| 09.04.2025 | Enabling Innovation: A Manufacturing Veteran’s Guide to Staying Ahead (Or Relevant) | 3 Shares Email Facebook Twitter LinkedIn By John Haddox Whether it’s the latest aircraft landing gears, hygienic air filters or smart-home devices, product designers are always on the hunt for new configurations that could become the “next ... |
| 25.03.2015 | This entrepreneur nearly lost his company. Here’s how litigation finance helped him fight back | In 2009, Chant, who had previously founded G-Zero Therapeutics (now G-One Therapeutics), heard about some tremendously promising technology being developed by researchers at the Dana-Farber Cancer Institute. It was a cancer drug candidate c... |
| 26.11.2012 | Repurposed diagnostic agent nears phase 3 trials as a treatment for melanoma | Although the Knoxville, Tennessee company doesn’t elaborate much on its immunotherapy’s mechanism of action, it says PV-10 is injected into lesions to selectively target and destroy cancer without harming healthy tissue. In phase 2 trials, ... |
| 01.03.2012 | Lilly’s big gamble: Will a risky drug for Alzheimer’s offset losses from generics? | Meanwhile, a competitor’s Alzheimer’s candidate is at the same point in the clinical trial process. Analysts suggest that success with solanezumab could make a secure future for Lilly in the Alzheimer’s treatment market. A failure, on the o... |
| 15.07.2011 | CNS pharma CoLucid names new CEO; aims for phase 3 trials on migraine drug | Mathers comes to Durham, North Carolina-based CoLucid from Peptimmune, a Massachusetts drug development company that was developing a new multiple sclerosis drug. Peptimmune filed for chapter 7 bankruptcy earlier this year after failing to ... |
| - | Lilly’s big gamble: Will a risky drug for Alzheimer’s offset losses from generics? | In the world of the pharma patent cliff, Eli Lilly & Co. (NYSE:LLY) stands in a particularly vulnerable spot. As the drugmaker awaits clinical trial results from a late-stage Alzheimer’s candidate, company leaders are faced with reports... |
| - | Repurposed diagnostic agent nears phase 3 trials as a treatment for melanoma | A compound used for years as a diagnostic agent for liver and eye cancer is nearing phase 3 clinical trials for a different purpose: to treat cancers and dermatological conditions. Provectus Pharmaceuticals Inc. (OTC BB:PVCT) is developing ... |
| - | This entrepreneur nearly lost his company. Here’s how litigation finance helped him fight back | This post is sponsored by Lake Whillans, a distressed venture finance firm that helps companies facing litigation or arbitration. As much as the landscape for biotechnology startups has changed over the last decade, one thing that hasn’t ch... |
| - | CNS pharma CoLucid names new CEO; aims for phase 3 trials on migraine drug | Central nervous system disorders pharmaceutical company CoLucid has named a new CEO who takes over a firm that is making progress on what is expected to be a breakthrough migraine headache treatment. Thomas Mathers takes the reins at Durham... |